Publications by authors named "Knut Eis"

Claim this Profile
S
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer.
Franziska Siegel, Stephan Siegel, Kristýna Kotýnková, Gizem Karsli Uzunbas, Daniel Korr, Knut Eis

Cancer Discov· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling.
Keith Graham, Philip Lienau, Benjamin Bader, Stefan Prechtl, Jan Naujoks, Joerg Weiske, Knut Eis

Cell Chem Biol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to "Discovery and Structure-Based Design of Potent Covalent PPARγ Inverse-Agonists BAY-4931 and BAY-0069".
Douglas L Orsi, Elisabeth Pook, Nico Bräuer, Anders Friberg, Philip Lienau, Knut Eis

J Med Chem· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonists.
Douglas L Orsi, Steven J Ferrara, Stephan Siegel, Anders Friberg, Léa Bouché, Knut Eis

Bioorg Med Chem· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Structure-Based Design of Potent Covalent PPARγ Inverse-Agonists and .
Douglas L Orsi, Elisabeth Pook, Nico Bräuer, Anders Friberg, Philip Lienau, Knut Eis

J Med Chem· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies.
Markus Berger, Lars Wortmann, Philipp Buchgraber, Ulrich Lücking, Sabine Zitzmann-Kolbe, Knut Eis, Gerhard Siemeister

J Med Chem· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Small Molecules that Modulate Mutant p53 Condensation.
Clara Lemos, Luise Schulze, Joerg Weiske, Hanna Meyer, Nico Braeuer, Thomas Markus Leissing, Knut Eis

iScience· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models.
Ulrich Lücking, Lars Wortmann, Antje M Wengner, Julien Lefranc, Philip Lienau, Gerhard Siemeister, Knut Eis

J Med Chem· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRAS.
Jérémie Mortier, Anders Friberg, Volker Badock, Dieter Moosmayer, Jens Schroeder, Knut Eis

ChemMedChem· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction.
Roman C Hillig, Brice Sautier, Jens Schroeder, Dieter Moosmayer, André Hilpmann, Joerg Weiske, Gerhard Siemeister, Knut Eis

Proc Natl Acad Sci U S A· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2- d]pyrimidine Based in Vitro Probe BAY-885 for the Kinase ERK5.
Duy Nguyen, Clara Lemos, Lars Wortmann, Knut Eis, Simon J Holton, Joerg Weiske

J Med Chem· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer.
Ulrich Lücking, Arne Scholz, Philip Lienau, Gerhard Siemeister, Dirk Kosemund, Knut Eis

ChemMedChem· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activity.
Susann Santag, Franziska Siegel, Antje M Wengner, Claudia Lange, Ulf Bömer, Knut Eis

Cancer Lett· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis.
Anna Santamaria, Rüdiger Neef, Uwe Eberspächer, Knut Eis, Manfred Husemann, Gerhard Siemeister

Mol Biol Cell· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Automated medicinal chemistry.
Marcus Koppitz, Knut Eis

Drug Discov Today· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinase data mining: dealing with the information (over-)flow.
Knut Eis, Stuart J Ince, Carsten Jahn, Rolf Jautelat, Vladimir Katchourovsky

Chembiochem· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis